Can the World Sustain HIV Progress? UNDP Urges Action as Prevention Funding Declines Worldwide

UNDP warns that shrinking global HIV funding is undermining access to life-saving prevention tools despite major scientific advances, shifting the challenge from innovation to sustainable implementation. The Rio AIDS Conference will test whether governments, donors and global health partners can strengthen financing, community-led healthcare and equitable access to keep the fight against HIV on track.

Scientific innovation has placed the global fight against HIV at a critical crossroads. While long-acting HIV prevention medicines now offer unprecedented opportunities to reduce new infections, the United Nations Development Programme (UNDP) warns that declining international health financing is threatening to erode decades of progress. Ahead of the 26th International AIDS Conference in Rio de Janeiro, the agency's message extends beyond HIV itself; it is a warning about the sustainability of global health financing, the resilience of health systems and the need for stronger partnerships between governments, donors and communities.

For global health partners, policymakers and healthcare stakeholders, the challenge is no longer limited to discovering better medicines. The greater test lies in mobilising resources, strengthening health systems and ensuring scientific breakthroughs reach vulnerable populations equitably. How countries respond today will influence not only HIV outcomes but also the future credibility of international health cooperation.

From Scientific Breakthroughs to Financing Gaps: The New HIV Challenge

The global HIV response has entered a new phase where financial sustainability is becoming as important as scientific progress. According to UNDP, international funding cuts over the past two years have forced many HIV prevention programmes to scale back despite the availability of highly effective long-acting pre-exposure prophylaxis (PrEP). UNAIDS data showing a 38% decline in PrEP uptake across 62 countries between 2024 and 2025 demonstrates that innovations alone cannot improve public health if countries lack the resources to deploy them.

For policymakers, this signals a shift from research-driven priorities toward investment-driven implementation. Governments that continue relying heavily on external donor funding may face increasing pressure to expand domestic health financing, integrate HIV services into broader universal health coverage programmes and improve healthcare efficiency. Failure to do so risks reversing progress in reducing HIV transmission while increasing long-term treatment costs.

The issue also reflects a wider trend across global health, where advances in medicine increasingly outpace the financial and institutional capacity needed to deliver them.

Global Health Partners Face Pressure to Rethink Funding and Collaboration

UNDP's warning places multilateral agencies, bilateral donors, philanthropic organisations and international financial institutions at the centre of the next phase of the HIV response. Traditional donor-funded models that have supported HIV programmes for decades are becoming more difficult to sustain as governments redirect resources toward multiple competing priorities, including pandemic preparedness, climate-related health challenges and non-communicable diseases.

Global health partners may therefore need to adopt more diversified financing approaches. Greater emphasis could be placed on blended financing, stronger domestic resource mobilisation, regional procurement mechanisms and partnerships that improve affordability of long-acting HIV prevention medicines.

The International AIDS Conference is also likely to encourage closer collaboration between UN agencies, UNAIDS, the Global Fund, the World Health Organization and national governments to ensure limited resources are allocated more strategically. Coordinated investments that strengthen primary healthcare systems rather than isolated disease-specific programmes may become increasingly important.

For international donors, maintaining support for HIV prevention is not only a health priority but also an investment in broader economic resilience, as preventing new infections reduces future healthcare expenditure and productivity losses.

Community-Led Healthcare Is Becoming a Strategic Policy Priority

One of the strongest messages emerging from UNDP's position is that community organisations should no longer be viewed merely as programme implementers but as strategic partners in healthcare delivery. Organisations working directly with vulnerable populations often possess the trust, local knowledge and social networks needed to reach groups that traditional healthcare systems struggle to serve.

The Prevention Manifesto launched by UNDP-supported organisations reinforces this shift by advocating for communities to participate directly in designing prevention strategies, identifying service gaps and ensuring equitable access to new technologies.

For policymakers, this requires expanding health governance beyond ministries and hospitals. Effective HIV prevention increasingly depends on partnerships between governments, civil society organisations, healthcare providers and local communities.

Healthcare stakeholders also benefit from stronger community engagement. Improved trust can increase HIV testing, encourage earlier diagnosis, improve treatment adherence and reduce disease transmission. These outcomes not only improve public health but also enhance the efficiency of national healthcare systems.

Policy Success Will Depend on Equity, Rights and Long-Term Investment

UNDP argues that ending AIDS requires addressing structural barriers that extend beyond medicine. Stigma, discrimination and laws that discourage vulnerable populations from accessing healthcare continue to limit the effectiveness of HIV prevention programmes in many countries.

For policymakers, this creates a broader governance challenge. Expanding access to long-acting PrEP and treatment requires legal environments that encourage people to seek healthcare without fear of discrimination or criminalisation. Public health outcomes increasingly depend on social inclusion, human rights protections and policies that reduce barriers to care.

For healthcare providers, integrating new HIV prevention technologies into routine services will require workforce training, improved supply chains and stronger health information systems. Pharmaceutical companies and manufacturers may also face increasing expectations to improve affordability and support wider access through pricing partnerships and technology transfer where appropriate.

Ultimately, the HIV funding debate reflects a larger question confronting global health governance. Scientific innovation has created the tools needed to substantially reduce HIV transmission, but achieving that objective now depends on political commitment, sustainable financing and coordinated partnerships. The decisions taken by governments, donors and global health institutions following the Rio conference will help determine whether the world maintains progress toward ending AIDS as a public health threat or enters a period of widening health inequalities and slower global progress.